Should you buy CRISPR Therapeutics stock now?
No, the technical signal for CRISPR Therapeutics is currently SELL. CRISPR Therapeutics trades at $51.96 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.726 with rising momentum (signal: -1.317); RSI is at 55.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $87.22 points to 67.9% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for CRISPR Therapeutics stock?
The average analyst price target for CRISPR Therapeutics is $87.22. The current price is $51.96, which gives an upside of 67.9%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $78.50 and $95.94.
Is CRISPR Therapeutics a dividend stock?
No, CRISPR Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of CRISPR Therapeutics stock?
CRISPR Therapeutics is rated as a stock with high risk. the annual standard deviation is 58.5%, which classifies the stock as high risk.
Is CRISPR Therapeutics overvalued?
No, CRISPR Therapeutics is considered undervalued based on the analyst price target (67.9% upside). CRISPR Therapeutics has the following valuation ratios: a P/S ratio of 1,273.8, a P/B ratio of 2.6. The analyst price target suggests that the stock is undervalued by 67.9%.
Is CRISPR Therapeutics overbought?
No, CRISPR Therapeutics is not overbought. RSI is at 55.6 (neutral zone). The technical indicators show: RSI is at 55.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 5.1% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next CRISPR Therapeutics earnings report?
The date of the next earnings report for CRISPR Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is CRISPR Therapeutics shorted?
Yes, CRISPR Therapeutics is shorted with 23.0% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying CRISPR Therapeutics stock?
No, insiders are not buying CRISPR Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 210,577 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 5,540,231 $ sold. Active sellers include Patel Naimish, Samarth Kulkarni, Prasad Raju and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is CRISPR Therapeutics a good stock?
Based on our total score, CRISPR Therapeutics is rated as a poor stock with a total score of 22 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 14/100, Quality: 21/100, Momentum: 31/100. In addition: analysts see 67.9% upside to the price target; technical signal: Strong Sell. Whether CRISPR Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for CRISPR Therapeutics stock?
The outlook for CRISPR Therapeutics based on current data: the average analyst price target is $87.22 (+67.9%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is CRISPR Therapeutics stock rising?
CRISPR Therapeutics is rising right now. The technical indicators show: the price is 5.1% above the 20-day average; short interest is 23.0% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can CRISPR Therapeutics go?
The average analyst price target for CRISPR Therapeutics is $87.22, which corresponds to a potential gain of 67.9% from the current price of $51.96. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can CRISPR Therapeutics fall?
We lack enough history to give a specific floor for CRISPR Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does CRISPR Therapeutics do?
CRISPR Therapeutics, eller crsp.us, udvikler genterapi mod alvorlige sygdomme. De bruger deres egen CRISPR/Cas9-platform, som præcist kan redigere i DNA'et. Det er grundlaget for, hvordan de tjener penge.
Deres pipeline dækker flere områder, blandt andet blodsygdomme og kræft... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate CRISPR Therapeutics as an investment.
Did CRISPR Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from CRISPR Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is CRISPR Therapeutics making money or losing money?
We have no current profitability data for CRISPR Therapeutics. See the latest report in the earnings history above.
Can CRISPR Therapeutics go bankrupt?
The bankruptcy risk of CRISPR Therapeutics is rated as low. Altman Z2 (a model for assessing financial distress) is 3.71 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 16% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does CRISPR Therapeutics have a lot of debt?
No, CRISPR Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 16%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
